Policies, practices, and challenges of systematic screening for TB disease: a global survey.

Introduction

Thank you for taking part in this global survey on behalf of your country's National TB Programme. The aim is to understand the policies, practices, and challenges of systematic screening for active TB disease in countries that report >1000 TB cases per year. This will provide important information for policymakers, funding agencies and academics involved in maximising the effectiveness of screening for active TB disease.

The survey has been developed by a team from University College London, FIND and WHO and has received ethical approval from the University College London Research Ethics Committee. The 2021 WHO guideline on systematic screening for TB disease serves as the benchmark for many of the questions.

The questions focus on systematic screening for active TB disease in your country (as opposed to screening for latent TB infection (LTBI)). We estimate that it will take you approximately 20 minutes to complete.

For the purposes of this survey systematic screening refers to: The systematic identification of active TB disease in people who are not seeking healthcare, through assessing symptoms and using tests, examinations or other procedures that can be applied rapidly. For those who screen positive, the diagnosis of TB disease then needs to be established by one or several diagnostic tests and additional clinical assessments. This is also known as active case finding and is distinguished from testing for latent TB infection.

For any queries please contact: mrcctu.NTPsurvey@ucl.ac.uk

Policies, practices, and challenges of systematic screening for TB disease: a global survey.

_		
General	∣ınt∩ı	rmation
Ochera		11162110711

General information		
1. Which country's Natio	onal TB Programme (NTP) are you answe	ering on behalf of?
2. Your job title and affil	iation(s)	
3. Please state your name	me and contact details. This information w	vill only be used to contact you about your
survey responses and v	will not be shared with any third parties.	
Name		
Email Address		
Phone Number		

Policies, practices, and challenges of systematic screening for TB disease: a global survey.

Policies and practices in relation to systematic screening for TB disease in your country


The questions in this section focus on your country's policies and practices in relation to systematic screening for active TB disease (not LTBI).

4. Prior to this survey, were you aware of the 2021 <u>WHO Guidelines</u> on systematic screening for active TB disease?
Yes
O No
5. Is systematic screening for active TB disease conducted in any form in your country?
Yes
○ No
6. Do you have a national strategic plan for TB
Yes
○ No
If answered "Yes" please state what time period the strategic plan covers
7. Dono voja potional atvetania plan for TD include a plan to cithan increase an decrease a retornation concerning
7. Does your national strategic plan for TB include a plan to either increase or decrease systematic screening for active TB disease?
Not applicable (no national strategic plan)
Increase systematic screening
Decrease systematic screening
No plan to increase or decrease
On't know
Other (please specify)

8. Do you have an existing national guideline that covers systematic screening for active TB disease?	
Yes	
○ No	
No - but we have a national policy or guideline in progress	
Other (please specify)	

9. In relation to implementing systematic screening for active TB disease which of the following steps have been carried out or are currently being carried out? *Please answer regardless of whether you have an existing policy for screening.* - see <u>chapter 2 of the WHO operational handbook for more information</u>. [Tick all that apply]

The six essential steps in the cycle of designing and implementing a TB screening programme (adapted from WHO Operational Handbook on Tuberculosis)



Situation assessment	Budgeting
Setting goals and specific objectives	Monitoring and evaluation
Identifying and prioritizing risk groups	None of the above
Choosing algorithms for screening and diagnosis	Not applicable

	Low priority	Neutral	High priority	Not applicable
General population with high TB prevalence (>0.5%)	0	\circ	0	0
People living with HIV		\bigcirc		\bigcirc
Household contacts (adults)		\circ	\circ	
Household contacts (children)	\bigcirc	\bigcirc	\bigcirc	\bigcirc
Prisons and penitentiary institutions		\circ	\circ	
Current and former workers in work places with silica exposure	\bigcirc	\bigcirc	\bigcirc	\bigcirc
People with clinical risk factors other than HIV seen in healthcare	0	0	0	0
People with untreated fibrotic lesions on CXR	\circ	\circ	\circ	\circ
Urban poor communities		\bigcirc		\bigcirc
Homeless communities				
Communities in remote or isolated areas		\circ	\circ	
Indigenous populations				
Migrants			\bigcirc	
Refugees			\bigcirc	
Internally displaced people			0	0
Other vulnerable or marginalized groups with limited access to healthcare				0

	In which of the following groups do you currently hase? [Tick all that apply]	ave a policy for systematic screening for active TB
uisc	Not applicable (no policy for systematic screening in place)	Urban poor communities
	General population with high TB prevalence (e.g. >0.5%)	Homeless communities
	People living with HIV	Communities in remote or isolated areas
	Household contacts (adults)	Indigenous populations
	Household contacts (children)	Migrants
	Prisons and penitentiary institutions	Refugees
	Current and former workers in work places with silica exposure	Internally displaced people
	People with clinical risk factors other than HIV seen in healthcare	Other vulnerable or marginalized groups with limited access to healthcare
	People with untreated fibrotic lesions on CXR	
	Other (please specify)	
activ	/e TB? [Tick all that apply] Government/ public health	
	Private sector	
	Non-Governmental Organisation	
	Academic institution	
	Other (please specify)	

13. Approximately what proportion of screening activity for active TB disease, regardless of who provides it, i reported to the National TB programme?
Not applicable (no screening activity)
All (100%)
Majority (75%)
Half (50%)
Minority (25%)
None (0%)
If all screening activity is not reported to NTP please comment on what the challenges are
14. What data does your NTP routinely collect for monitoring and evaluating your systematic screening programme for active TB disease? [Tick all that apply]
No data is collected for monitoring of systematic screening
Number of people eligible for screening according to national guidance
Number of people screened for TB (total)
Number of people screened by risk group (e.g. contacts, PLHIV, migrants etc)
Number of people screened by the screening tool used (e.g. CXR vs symptoms only)
Number of people who screen positive for TB (i.e. requiring confirmatory testing)
Number of people evaluated for TB disease (i.e. receiving confirmatory testing)
Number of people diagnosed with TB (total, including clinical and bacteriological diagnosis)
Number of people diagnosed with TB by bacteriological status (i.e. confirmed or not)
Number of people diagnosed with TB classified by symptom status
Number of people started on TB treatment
Number of people successfully completing TB treatment
Other (please specify)

	s systematic screening for active TB disease budgeted in your National TB budget?
	Not applicable (no screening)
\bigcirc	Yes
\bigcirc	No
\bigcirc	Partially
\bigcirc	Don't know
\bigcirc	Other (please specify)
16. V	What is the source of funding within the National TB budget for systematic screening activity for active
TB?	
0	Not applicable
\bigcirc	Domestic funding
\bigcirc	International donor funding (including the Global Fund)
	Mixture of domestic and international funding
	Unfunded
	Other (please specify)
	e specify other sources of funding and describe the approximate proportion of funding if mixed, for example: 50% domestic ng, 50% international.
	Going forward, has the priority for systematic screening for active TB changed due to the COVID lemic?
\bigcirc	Increased priority
	Not affected priority
\bigcirc	Not affected priority Reduced priority
0	
	Reduced priority
Pleas	Reduced priority Don't know
Pleas	Reduced priority Don't know Other
Pleas	Reduced priority Don't know Other

Policies, practices, and challenges of systematic screening for TB disease: a global survey.

Tools and algorithms used for systematic screening for active TB disease in your country

The questions in this section focus on your country's use of screening tools for active TB disease,
focusing on the following population groups: Adult contacts; child contacts; people living with HIV

(PLHIV); and other relevant risk groups you feel are screened differently for active TB in your country.

For the purposes of this survey the following definitions apply:

<u>Prolonged cough:</u> Cough lasting \geq 2 weeks (please use the comments box to detail any alternative definitions e.g. if your country defines prolonged cough as lasting \geq 3 weeks).

<u>Any TB symptoms:</u> Cough of any duration, sputum, haemoptysis, fever, night sweats or weight loss. <u>W4SS:</u> WHO-recommended four-symptom-screen, comprising screening for a current cough, fever, night sweats or weight loss.

18. Which symptoms do you use to screen for active TB disease? This applies to the following populations: Adult contacts of TB cases, child contacts of TB cases, PLHIV, and any other relevant risk groups. [Please select 'yes' from the dropdown menu where applicable, otherwise leave the box blank]

	Adult contacts	Child contacts	PLHIV	Other risk groups
Prolonged cough	\$	\$	\$	\$
Any cough	\$	\$	\$	\$
Any TB symptom	\$	\$	\$	\$
W4SS (for PLHIV only)	\$	\$	•	\$
We do not ask about symptoms	•	•	•	•

Comments (if applicable). For example, if you use symptoms to screen in any other population group or scenario, please provide that information here.

٠.	•	٦
1	ı	п

	Adult contacts	PLHIV	Children contacts	Other risk groups
all people being screened	\$	\$	\$	•
People with a positive symptom screen (see question 17)	\$	\$	\$	\$
People with a negative symptom screen (see question 17)	\$	\$	\$	•
People with a positive bacteriological test	\$	\$	\$	•
We do not use CXR as a screening tool in this context	•	\$	\$	•
omments (if applicable). For ovide that information here.	example, if you use CXR	to screen in any other p	opulation group or scenario,	please
•	•	•	•	-
B disease (as opposed ases, PLHIV and any 'c	to as confirmatory to ther' groups. [Please	ests)? This applies to select 'yes' from the	to the following populati	ions: Contacts of TE
3 disease (as opposed ases, PLHIV and any 'c herwise leave the box	to as confirmatory to ther' groups. [Please blank]	ests)? This applies to select 'yes' from the	to the following populati ne dropdown menu whe	ions: Contacts of TE ere applicable,
B disease (as opposed ases, PLHIV and any 'cherwise leave the box	to as confirmatory to other' groups. [Please blank]	ests)? This applies to select 'yes' from the	to the following population the dropdown menu when the control of	ions: Contacts of TE ere applicable,
B disease (as opposed ases, PLHIV and any 'continuous therwise leave the box all people being screened all medical inpatients where TB prevalence is high (for PLHIV only) We do not use molecular	to as confirmatory to other' groups. [Please blank]	ests)? This applies to select 'yes' from the	to the following population the dropdown menu whe	ions: Contacts of TE ere applicable,
B disease (as opposed ases, PLHIV and any 'continuous leave the box all people being screened all medical inpatients where TB prevalence is high (for PLHIV only). We do not use molecular diagnostics as screening tests for active TB.	to as confirmatory to ther groups. [Please blank] Contacts	ests)? This applies to select 'yes' from the	to the following population the dropdown menu when the public states of the following population of the dropdown menu when the public states of the following population of the following population of the dropdown menu when the public states of the following population of the dropdown menu when the following population of the dropdown menu when the public states of the following population of the dropdown menu when the public states of the dropdown menu when the following population of the dropdown menu when the dropdown me	ons: Contacts of TE ere applicable, Other
where TB prevalence is high (for PLHIV only) We do not use molecular diagnostics as screening	to as confirmatory to ther groups. [Please blank] Contacts	ests)? This applies to select 'yes' from the	to the following population the dropdown menu when the public states of the following population of the dropdown menu when the public states of the following population of the following population of the dropdown menu when the public states of the following population of the dropdown menu when the following population of the dropdown menu when the public states of the following population of the dropdown menu when the public states of the dropdown menu when the following population of the dropdown menu when the dropdown me	ons: Contacts of TE ere applicable, Other

19. Where do you use CXR in your screening algorithm for active TB disease? This applies to the following

Yes No Don't know Comments (if applicable) 22. What confirmatory bacteriological tests for active TB disease are routinely used in people screpositive in your country? [Tick all that apply] Not applicable Smear Culture (MGIT) Culture (solid) Molecular (Xpert MTB/RIF) Molecular (Xpert Ultra) Molecular (Truenat) Molecular (other - please specify in the comments box below) Not stated in guidelines Other (please specify in the comments box below) Comments (if applicable)	ole screeni
Comments (if applicable) 22. What confirmatory bacteriological tests for active TB disease are routinely used in people scree positive in your country? [Tick all that apply] Not applicable Smear Culture (MGIT) Culture (solid) Molecular (Xpert MTB/RIF) Molecular (Xpert Ultra) Molecular (Truenat) Molecular (other - please specify in the comments box below) Not stated in guidelines Other (please specify in the comments box below)	ole screeni
22. What confirmatory bacteriological tests for active TB disease are routinely used in people screen positive in your country? [Tick all that apply] Not applicable Smear Culture (MGIT) Culture (solid) Molecular (Xpert MTB/RIF) Molecular (Xpert Ultra) Molecular (Truenat) Molecular (other - please specify in the comments box below) Not stated in guidelines Other (please specify in the comments box below)	ole screeni
22. What confirmatory bacteriological tests for active TB disease are routinely used in people screen positive in your country? [Tick all that apply] Not applicable Smear Culture (MGIT) Culture (solid) Molecular (Xpert MTB/RIF) Molecular (Xpert Ultra) Molecular (Truenat) Molecular (other - please specify in the comments box below) Not stated in guidelines Other (please specify in the comments box below)	ole screeni
Not applicable Smear Culture (MGIT) Culture (solid) Molecular (Xpert MTB/RIF) Molecular (Truenat) Molecular (other - please specify in the comments box below) Other (please specify in the comments box below)	ole screeni
Not applicable Smear Culture (MGIT) Culture (solid) Molecular (Xpert MTB/RIF) Molecular (Truenat) Molecular (other - please specify in the comments box below) Other (please specify in the comments box below)	ole screeni
Not applicable Smear Culture (MGIT) Culture (solid) Molecular (Xpert MTB/RIF) Molecular (Truenat) Molecular (other - please specify in the comments box below) Other (please specify in the comments box below)	ole screeni
Not applicable Smear Culture (MGIT) Culture (solid) Molecular (Xpert MTB/RIF) Molecular (Truenat) Molecular (other - please specify in the comments box below) Other (please specify in the comments box below)	ole screeni
Not applicable Smear Culture (MGIT) Culture (solid) Molecular (Xpert MTB/RIF) Molecular (Xpert Ultra) Molecular (Truenat) Molecular (other - please specify in the comments box below) Not stated in guidelines Other (please specify in the comments box below)	
Culture (MGIT) Culture (solid) Molecular (Xpert MTB/RIF) Molecular (Xpert Ultra) Molecular (Truenat) Molecular (other - please specify in the comments box below) Not stated in guidelines Other (please specify in the comments box below)	
Culture (solid) Molecular (Xpert MTB/RIF) Molecular (Xpert Ultra) Molecular (Truenat) Molecular (other - please specify in the comments box below) Not stated in guidelines Other (please specify in the comments box below)	
Culture (solid) Molecular (Xpert MTB/RIF) Molecular (Xpert Ultra) Molecular (Truenat) Molecular (other - please specify in the comments box below) Not stated in guidelines Other (please specify in the comments box below)	
Molecular (Xpert Ultra) Molecular (Truenat) Molecular (other - please specify in the comments box below) Not stated in guidelines Other (please specify in the comments box below)	
Molecular (Truenat) Molecular (other - please specify in the comments box below) Not stated in guidelines Other (please specify in the comments box below)	
Molecular (other - please specify in the comments box below) Not stated in guidelines Other (please specify in the comments box below)	
Not stated in guidelines Other (please specify in the comments box below)	
Other (please specify in the comments box below)	

Policies, practices, and challenges of systematic screening for TB disease: a global survey.

The use of CXR technologies for screening for active TB disease in your country. The questions in this section focus on the use of CXR technologies in your country.

For the purposes of this survey the following definitions apply:

<u>Computer-Aided Detection (CAD):</u> The use of specialised software to interpret abnormalities on digital chest radiographs that are suggestive of TB. The results are expressed as abnormality scores.

23. Is	implementing or expanding the use of CXR for systematic screening for active TB disease part of your
nation	nal strategic plan?
\bigcirc ,	Yes
O 1	No
<u> </u>	Don't know
diseas	That are the barriers to implementing or expanding CXR based systematic screening for active TB se in your country? Please answer regardless of whether you have an existing policy for screening. [Tick apply]
	High equipment costs
	Funding
	Access to radiologists
	Access to radiographers
	Lack of laboratory infrastructure for bacteriological testing following CXR
	Regulatory or procurement issues
	Perceived limited impact of CXR screening
	Concerns about increases in empirical TB treatment
	Patient factors (e.g cost to individual)
	Safety concerns regarding radiation dose
	Low community access to CXR
	There are no barriers
	Other (please specify)

Not applicable - not using CXR for screening No - using CXR from screening but not using CAD No - but planning to pilot use of CAD Only using in research settings or as a pilot Yes - using in some private sector settings Yes - using in some public sector settings Yes - using in some public sector settings Yes - in most settings for TB screening omment (if applicable) 6. What are the barriers and concerns regarding implementation of CAD in screening for active TB in all ettings? [Tick all that apply] We are not aware of this technology Digital CXR not currently being used Lack of validation in all age groups Sufficient expertise and availability of radiologists exists Too expensive Poor specificity Poor predictive value Regulatory issues Connectivity (internet) issues Procurement issues Insufficient infrastructure Concerns about data security There are no barriers Other (please specify)	25. If CXR is used in systematic screening for active TB, is CAD used to inform management	t decisions?
No – but planning to pilot use of CAD Only using in research settings or as a pilot Yes - using in some private sector settings Yes - using in some public sector settings Yes - in most settings for TB screening omment (if applicable) 6. What are the barriers and concerns regarding implementation of CAD in screening for active TB in all ettings? [Tick all that apply] We are not aware of this technology Digital CXR not currently being used Lack of validation in all age groups Sufficient expertise and availability of radiologists exists Too expensive Poor specificity Poor predictive value Regulatory issues Connectivity (internet) issues Procurement issues Insufficient infrastructure Concerns about data security There are no barriers	Not applicable - not using CXR for screening	
Only using in research settings or as a pilot Yes - using in some private sector settings Yes - using in some public sector settings Yes - in most settings for TB screening omment (if applicable) 6. What are the barriers and concerns regarding implementation of CAD in screening for active TB in all ettings? [Tick all that apply] We are not aware of this technology Digital CXR not currently being used Lack of validation in all age groups Sufficient expertise and availability of radiologists exists Too expensive Poor specificity Poor predictive value Regulatory issues Connectivity (internet) issues Procurement issues Insufficient infrastructure Concerns about data security There are no barriers	No - using CXR from screening but not using CAD	
Yes - using in some private sector settings Yes - in most settings for TB screening omment (if applicable) 6. What are the barriers and concerns regarding implementation of CAD in screening for active TB in all ettings? [Tick all that apply] We are not aware of this technology Digital CXR not currently being used Lack of validation in all age groups Sufficient expertise and availability of radiologists exists Too expensive Poor specificity Poor predictive value Regulatory issues Connectivity (internet) issues Insufficient infrastructure Concerns about data security There are no barriers	No – but planning to pilot use of CAD	
Yes - using in some public sector settings Yes - in most settings for TB screening comment (if applicable) 6. What are the barriers and concerns regarding implementation of CAD in screening for active TB in all ettings? [Tick all that apply] We are not aware of this technology Digital CXR not currently being used Lack of validation in all age groups Sufficient expertise and availability of radiologists exists Too expensive Poor specificity Poor predictive value Regulatory issues Connectivity (internet) issues Procurement issues Insufficient infrastructure Concerns about data security There are no barriers	Only using in research settings or as a pilot	
Yes - in most settings for TB screening omment (if applicable) 6. What are the barriers and concerns regarding implementation of CAD in screening for active TB in all ettings? [Tick all that apply] We are not aware of this technology Digital CXR not currently being used Lack of validation in all age groups Sufficient expertise and availability of radiologists exists Too expensive Poor specificity Poor predictive value Regulatory issues Connectivity (internet) issues Insufficient infrastructure Concerns about data security There are no barriers	Yes - using in some private sector settings	
6. What are the barriers and concerns regarding implementation of CAD in screening for active TB in all ettings? [Tick all that apply] We are not aware of this technology Digital CXR not currently being used Lack of validation in all age groups Sufficient expertise and availability of radiologists exists Too expensive Poor specificity Poor predictive value Regulatory issues Connectivity (internet) issues Procurement issues Insufficient infrastructure Concerns about data security There are no barriers	Yes - using in some public sector settings	
6. What are the barriers and concerns regarding implementation of CAD in screening for active TB in all ettings? [Tick all that apply] We are not aware of this technology Digital CXR not currently being used Lack of validation in all age groups Sufficient expertise and availability of radiologists exists Too expensive Poor specificity Poor predictive value Regulatory issues Connectivity (internet) issues Insufficient infrastructure Concerns about data security There are no barriers	Yes - in most settings for TB screening	
6. What are the barriers and concerns regarding implementation of CAD in screening for active TB in all ettings? [Tick all that apply] We are not aware of this technology Digital CXR not currently being used Lack of validation in all age groups Sufficient expertise and availability of radiologists exists Too expensive Poor specificity Poor predictive value Regulatory issues Connectivity (internet) issues Insufficient infrastructure Concerns about data security There are no barriers		
ettings? [Tick all that apply] We are not aware of this technology Digital CXR not currently being used Lack of validation in all age groups Sufficient expertise and availability of radiologists exists Too expensive Poor specificity Poor predictive value Regulatory issues Connectivity (internet) issues Procurement issues Insufficient infrastructure Concerns about data security There are no barriers	Comment (ii applicable)	
ettings? [Tick all that apply] We are not aware of this technology Digital CXR not currently being used Lack of validation in all age groups Sufficient expertise and availability of radiologists exists Too expensive Poor specificity Poor predictive value Regulatory issues Connectivity (internet) issues Procurement issues Insufficient infrastructure Concerns about data security There are no barriers		
ettings? [Tick all that apply] We are not aware of this technology Digital CXR not currently being used Lack of validation in all age groups Sufficient expertise and availability of radiologists exists Too expensive Poor specificity Poor predictive value Regulatory issues Connectivity (internet) issues Procurement issues Insufficient infrastructure Concerns about data security There are no barriers		
Lack of validation in all age groups Sufficient expertise and availability of radiologists exists Too expensive Poor specificity Poor predictive value Regulatory issues Connectivity (internet) issues Procurement issues Insufficient infrastructure Concerns about data security There are no barriers		
Lack of validation in all age groups Sufficient expertise and availability of radiologists exists Too expensive Poor specificity Poor predictive value Regulatory issues Connectivity (internet) issues Procurement issues Insufficient infrastructure Concerns about data security There are no barriers		
Too expensive Poor specificity Poor predictive value Regulatory issues Connectivity (internet) issues Procurement issues Insufficient infrastructure Concerns about data security There are no barriers		
Poor specificity Poor predictive value Regulatory issues Connectivity (internet) issues Procurement issues Insufficient infrastructure Concerns about data security There are no barriers	Sufficient expertise and availability of radiologists exists	
Poor predictive value Regulatory issues Connectivity (internet) issues Procurement issues Insufficient infrastructure Concerns about data security There are no barriers	Too expensive	
Regulatory issues Connectivity (internet) issues Procurement issues Insufficient infrastructure Concerns about data security There are no barriers	Poor specificity	
Connectivity (internet) issues Procurement issues Insufficient infrastructure Concerns about data security There are no barriers	Poor predictive value	
Procurement issues Insufficient infrastructure Concerns about data security There are no barriers	Regulatory issues	
Insufficient infrastructure Concerns about data security There are no barriers	Connectivity (internet) issues	
Concerns about data security There are no barriers	Procurement issues	
There are no barriers	Insufficient infrastructure	
	Concerns about data security	
Other (please specify)	There are no barriers	
	Other (please specify)	

THIS PDF IS FOR REFERENCE ONLY. Please complete the survey online. Policies, practices, and challenges of systematic screening for TB disease: a global survey. Thank you for taking the time to complete this survey. 27. Are you happy for us to contact you about your answers? Yes